Enhancing immune effects of a DNA vaccine against kidney cancer using CD40L as an adjuvant
Braz. J. Pharm. Sci. (Online)
;
55: e18173, 2019. graf
Artículo
en Inglés
| LILACS
| ID: biblio-1039035
ABSTRACT
The use of specific combinations of antigens and adjuvant represents a promising approach for increasing the immunogenicity of DNA vaccines. In the present study, we evaluated the immunity and antitumor effects of DNA vaccines with G250 as the target antigen in a mouse model of renal cell carcinoma. We constructed two recombinant plasmids, pVAX1-G250 and pVAX1-CD40L. The recombinant plasmids were injected into mice by intramuscular injection and electrical pulse stimulation. ELISA and ELISPOT experiments were performed to evaluate the corresponding humoral and cellular immune responses following immunization. To further investigate the antitumor potential of the DNA vaccines, we established a tumor-bearing mouse model expressing G250 target antigen. Our results showed that immunization with the combination of the two plasmids exerted the strongest anti-tumor effects. Therefore, our findings demonstrated the effectiveness of CD40L as an adjuvant for DNA vaccines and highlighted the promising use of these vaccines for the treatment of tumors.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
ADN
/
Vacunas
/
Inmunidad
/
Neoplasias Renales
Tipo de estudio:
Estudio pronóstico
Límite:
Animales
Idioma:
Inglés
Revista:
Braz. J. Pharm. Sci. (Online)
Asunto de la revista:
Farmacologia
/
Teraputica
/
Toxicologia
Año:
2019
Tipo del documento:
Artículo
País de afiliación:
China
Institución/País de afiliación:
Daqing Oilfield General Hospital/CN
Similares
MEDLINE
...
LILACS
LIS